A retrospective study analyzing outcomes of classical Hodgkin lymphoma treated with brentuximab vedotin plus nivolumab
Latest Information Update: 19 Jul 2022
At a glance
- Drugs Brentuximab vedotin (Primary) ; Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
Most Recent Events
- 19 Jul 2022 New trial record
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology